INDIANAPOLIS and CAMBRIDGE, Mass., Aug. 31, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Merida Biosciences, Inc. (Merida), a biotechnology company advancing a new class of precision therapeutics for serious autoimmune and allergic diseases, today announced a definitive agreement for Lilly to acquire Merida.
https://investor.lilly.com/news-releases/news-release-details/lilly-acquire-merida-biosciences-advance-treatments-serious